156 related articles for article (PubMed ID: 23255844)
1. Risk factors for febrile neutropenia during chemotherapy for HIV-related lymphoma.
Park J; Kim TM; Hwang JH; Kim NH; Choe PG; Song KH; Kim ES; Park SW; Kim HB; Kim NJ; Park WB; Oh MD
J Korean Med Sci; 2012 Dec; 27(12):1468-71. PubMed ID: 23255844
[TBL] [Abstract][Full Text] [Related]
2. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy.
Lyman GH; Morrison VA; Dale DC; Crawford J; Delgado DJ; Fridman M; ;
Leuk Lymphoma; 2003 Dec; 44(12):2069-76. PubMed ID: 14959849
[TBL] [Abstract][Full Text] [Related]
3. Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy.
Sparano JA; Hu X; Wiernik PH; Sarta C; Reddy DM; Hanau L; Henry DH
J Natl Cancer Inst; 1997 Feb; 89(4):301-7. PubMed ID: 9048834
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.
Ravaud A; Chevreau C; Cany L; Houyau P; Dohollou N; Roché H; Soubeyran P; Bonichon F; Mihura J; Eghbali H; Tabah I; Bui BN
J Clin Oncol; 1998 Sep; 16(9):2930-6. PubMed ID: 9738560
[TBL] [Abstract][Full Text] [Related]
5. Febrile neutropenia in a HIV positive individual post-chemotherapy.
Ridha E; Cookson H; Devitt E; Nelson M
J Clin Virol; 2010 May; 48(1):2-5. PubMed ID: 20171139
[No Abstract] [Full Text] [Related]
6. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
[TBL] [Abstract][Full Text] [Related]
7. [Prevention and treatment of febrile neutropenia].
Montemurro F; Gallicchio M; Aglietta M
Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
[TBL] [Abstract][Full Text] [Related]
8. Outcome for hospitalized patients with fever and neutropenia who are infected with the human immunodeficiency virus.
Hambleton J; Aragón T; Modin G; Northfelt DW; Sande MA
Clin Infect Dis; 1995 Feb; 20(2):363-71. PubMed ID: 7742443
[TBL] [Abstract][Full Text] [Related]
9. Incidence and spectrum of infections among HIV/AIDS patients with lymphoma during chemotherapy.
Wang Z; Zhang R; Liu L; Shen Y; Chen J; Qi T; Song W; Tang Y; Sun J; Lin Y; Xu S; Yang J; Lu H
J Infect Chemother; 2021 Oct; 27(10):1459-1464. PubMed ID: 34158238
[TBL] [Abstract][Full Text] [Related]
10. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer.
Borg C; Ray-Coquard I; Philip I; Clapisson G; Bendriss-Vermare N; Menetrier-Caux C; Sebban C; Biron P; Blay JY
Cancer; 2004 Dec; 101(11):2675-80. PubMed ID: 15503313
[TBL] [Abstract][Full Text] [Related]
11. Frequency and risk factors of infectious complications in neutropenic patients infected with HIV.
Meynard JL; Guiguet M; Arsac S; Frottier J; Meyohas MC
AIDS; 1997 Jul; 11(8):995-8. PubMed ID: 9223733
[TBL] [Abstract][Full Text] [Related]
12. Low-risk febrile neutropenia in a medical oncology unit.
Leong DC; Kinlay S; Ackland S; Bonaventura A; Stewart JF
Aust N Z J Med; 1997 Aug; 27(4):403-7. PubMed ID: 9448881
[TBL] [Abstract][Full Text] [Related]
13. Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma.
Montoto S; Wilson J; Shaw K; Heath M; Wilson A; McNamara C; Orkin C; Nelson M; Johnson M; Bower M; Cwynarski K
AIDS; 2010 Mar; 24(6):851-6. PubMed ID: 20124971
[TBL] [Abstract][Full Text] [Related]
14. International prognostic index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP. A multivariate study of 46 patients.
Navarro JT; Ribera JM; Oriol A; Vaquero M; Romeu J; Batlle M; Gómez J; Millá F; Feliu E
Haematologica; 1998 Jun; 83(6):508-13. PubMed ID: 9676023
[TBL] [Abstract][Full Text] [Related]
15. [Colony-stimulating factors and HIV-related neoplasms].
Valencia ME; Moreno V; Soriano V; Polo R; Verdejo J; Laguna F; González Lahoz J
An Med Interna; 1996 Jul; 13(7):317-21. PubMed ID: 8962975
[TBL] [Abstract][Full Text] [Related]
16. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
Lyman GH; Delgado DJ
Cancer; 2003 Dec; 98(11):2402-9. PubMed ID: 14635075
[TBL] [Abstract][Full Text] [Related]
17. Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone without routine use of granulocyte-colony stimulating factor.
Hernàndez DE; Hernàndez AE
Eur J Cancer Care (Engl); 2006 Dec; 15(5):493-6. PubMed ID: 17177909
[TBL] [Abstract][Full Text] [Related]
18. Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients.
de Souza Viana L; Serufo JC; da Costa Rocha MO; Costa RN; Duarte RC
Support Care Cancer; 2008 Jul; 16(7):841-6. PubMed ID: 17960431
[TBL] [Abstract][Full Text] [Related]
19. Management of febrile neutropenia in patients receiving chemotherapy for solid tumors: a retrospective study of twenty cases from the radiotherapy centre, Accra, Ghana.
Vanderpuye V; Yarney J; Beecham K
West Afr J Med; 2010; 29(5):303-8. PubMed ID: 21089015
[TBL] [Abstract][Full Text] [Related]
20. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
